KMI169 is a potent and selective inhibitor targeting lysine methyl-transferase (KMT9) (IC50 = 0.05 µM, Kd = 0.025 µM). KMI169 functions as a bi-substrate inhibitor targeting the cofactor S-5-adenosyl-L-methionine (SAM) and substrate binding pockets of KMT9. KMI169 can downregulate target genes involved in cell cycle regulation and impair proliferation of tumor cells by inhibiting KMT9. KMI169 is a valuable tool to probe cellular KMT9 functions and can be research for combating diseases including prostate, lung, colon, and invasive bladder cancer[1][2].
Molekulargewicht:
604.53
Reinheit:
98.00
Formel:
C31H31Cl2N7O2
Target-Kategorie:
Epigenetic Reader Domain
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
